DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20184187

Amisulpiride induced tardive dyskinesia: a case report

Dhananjay Chaudhari, Ganesh Shanker, Kunjan Gupta

Abstract


Amisulpride is a bezamide group of antipsychotic, and like other antipsychotics, it acts by reducing signalling via the dopamine D2 receptor. It is associated with a high risk, of developing increased blood levels of the lactation hormone, prolactin and low risk, as compared with typical antipsychotics, of causing movement disorders. Tardive dyskinesia is a type of movement disorder, which is more common with typical antipsychotics but development of tardive dyskinesia is not rare with the use of atypical antipsychotics. Newer molecules are being developed to reduce the incidence of various dyskinesias, but side effects are evident even with relatively newer molecules. Amisupride is also classed with newer generation of atypical antipsychotic, used to treat schizophrenia and dysthymia. We are reporting a case of middle aged female patient suffering from schizophrenia who developed tardive dyskinesia with the use of amisulpride.


Keywords


Amisulpiride, Tardive dyskinesia

Full Text:

PDF

References


Daniel DG, Egan MF, Wolf SS. Neuropsychiatric aspects of movement disorders. In: Comprehensive Textbook of Psychiatry. 7th Ed, Lippincott Williams and Wilkins, Philadelphia, USA. 2000.

American Psychiatric Association. diagnostic and statistical manual of mental disorders, 5th Ed, Arlington, VA: American Psychiatric Association. 2013.

Washington, DC. American Psychiatric Association. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th Ed, Text Revision (DSM-IV-TR). 2000:803-805.

Kulkarni SK, Naidu PS. Pathophysiology and drug therapy of tardive dyskinesia: current concepts and future perspectives. Drugs Today (Barc). 2003 Jan 1;39(1):19-49.

Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004 Mar 1;161(3):414-25.

Tenback DE, Bakker PR, van Harten PN. Risk factors for tardive movement disorders in schizophrenia. Tijdschr Psychiatr. 2015;57(2):120- 4.

Peña MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord. 2011 Jan;26(1):147-52.

Masdrakis VG, Papadimitriou GN, Papageorgiou C, Kouzoupis A, Giailoglou D, Soldatos CR. Development of tardive dyskinesia in a patient taking amisulpride. Prog Neuropsychopharmacol Biolog Psychiatr. 2007;2(31):586-7.

Fountoulakis KN, Panagiotidis P, Siamouli M, Kantartzis S, Mavridis T, Iacovides A, et al. Amisulpride-induced tardive dyskinesia. Schizophrenia Res. 2006 Dec 1;88(1-3):232-4.